NCT03813940View on ClinicalTrials.gov

Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

August 18, 2019

Study Completion Date

April 1, 2021

Conditions
Condylomata AcuminataCervical Cancer
Interventions
BIOLOGICAL

HPV Vaccine,135μg/0.5ml

HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule

BIOLOGICAL

HPV Vaccine,270μg/1.0ml

HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule

Trial Locations (1)

210009

Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Xiamen University

OTHER

NCT03813940 - Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | Biotech Hunter | Biotech Hunter